annb0t
Top 20
Immutep Limited
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activity Biomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longer Four world leading oncologists join the Clinical Advisory Board Well-funded with ~$80 million in cash, giving Immutep an expected cas...
>>> Read more: Immutep Quarterly Activities Report
Phase II TACTI-002 trial met its primary objective in 1st line non-small cell lung cancer (NSCLC) patients, with 38.6% Overall Response Rate and favourable anti-tumour activity Biomarker and multivariate analysis data from the completed Phase IIb AIPAC trial reported, confirming efti is activating the immune system and helping patients live longer Four world leading oncologists join the Clinical Advisory Board Well-funded with ~$80 million in cash, giving Immutep an expected cas...
>>> Read more: Immutep Quarterly Activities Report
